alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 99.1
 REPROS PROVIDES UPDATE FOR REGULATORY PROGRAM ASSOCIATED
WITH ANDROXAL DEVELOPMENT
  About Repros Therapeutics Inc.
 ®
 ® ®
   Any statements that are not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including Repros ability to have success in the
clinical development of its technologies, the timing of enrollment in such clinical studies and the
accuracy of such studies, Repros ability to raise additional capital on acceptable terms or at
all, and such other risks which are identified in the Companys Annual Report on Form 10-K for the
year ended December 31, 2006, and Repros Quarterly Reports on Form 10-Q for the quarters ended
March 31 and June 30, 2007, as they may be updated by the Companys Exchange Act filings from time
to time. These documents are available on request from Repros Therapeutics or at www.sec.gov.
Repros disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
 Contact:
    
    Joseph S. Podolski
President & CEO
(281) 719-3447
[Federal Register Volume 89, Number 188 (Friday, September 27, 2024)]
[Notices]
[Pages 79299-79300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22139]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Investigator Initiated 
Program Project Applications (P01 Clinical Trial Not Allowed).

[[Page 79300]]

    Date: November 26, 2024.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G56, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Maryam Rohani, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD 
20892, (301) 761-6656, <a href="/cdn-cgi/l/email-protection#0f626e7d766e62217d60676e61664f61666721686079"><span class="__cf_email__" data-cfemail="d9b4b8aba0b8b4f7abb6b1b8b7b099b7b0b1f7beb6af">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: September 23, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-22139 Filed 9-26-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                           1,069
<SECURITIES>                                         0
<RECEIVABLES>                                    9,476
<ALLOWANCES>                                       719
<INVENTORY>                                     68,115
<CURRENT-ASSETS>                                82,528
<PP&E>                                           2,774
<DEPRECIATION>                                     958
<TOTAL-ASSETS>                                  94,594
<CURRENT-LIABILITIES>                           35,490
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           111
<OTHER-SE>                                      55,839
<TOTAL-LIABILITY-AND-EQUITY>                    94,594
<SALES>                                         48,982
<TOTAL-REVENUES>                                48,982
<CGS>                                           35,475
<TOTAL-COSTS>                                   35,475
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   (14)
<INTEREST-EXPENSE>                                 816
<INCOME-PRETAX>                                  6,583
<INCOME-TAX>                                     2,437
<INCOME-CONTINUING>                              4,146
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,146
<EPS-PRIMARY>                                     0.37
<EPS-DILUTED>                                     0.37
        

</TABLE>
EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kitcher Resources Inc. (the
"Company") on Form 10-QSB for the period ending April 30, 2007 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Raminder Badyal, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002,
that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

IN WITNESS WHEREOF, the undersigned has executed this certification as of the
11th day of June, 2007.


/s/ Raminder Badyal
-----------------------------
Chief Financial Officer
# C_2022306EN.01000101.xml

| 11.8.2022 | EN | Official Journal of the European Union | C 306/1 |
| --- | --- | --- | --- |

11.8.2022

EN

Official Journal of the European Union

C 306/1

---

Non-opposition to a notified concentration

(Case M.10745 – EMIL FREY / FCA CENTRAL AND EASTERN EUROPE / FIAT CHRYSLER AUTOMOBILES CR / FIAT CHRYSLER AUTOMOBILES SR)

(Text with EEA relevance)

(2022/C 306/01)

On 29 July 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10745. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10745. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
##### 



Exhibit 10.16
 EMPLOYMENT AGREEMENT
(J. Michael Pearson)
 EMPLOYMENT AGREEMENT Agreement Company Key
Employee Effective Date Financing provided
 W I
T N E S S E T H:
 WHEREAS,
 WHEREAS,
 NOW, THEREFORE,
 ARTICLE I
DEFINITIONS AND INTERPRETATIONS
 1.1 Definitions .
 Base Salary Section 2.3(a)
 Board
 Cause
 Section 3.8
    1




---



##### 



Change in Control
 Section
1.1(d)(ii) provided further however Section
1.1(d)(i) Section 1.1(d)(i)
 Section 1.1(d)(ii) Section
1.1(d)(i)
  2




---



##### 



Section 1.1(d) provided Section 1.1(d) Majority Shareholder (y) (y)
 Code
 Disability Company Physician Key Employees Physician
 Good Reason
    Nonqualified Deferred Compensation Rules
 3




---



##### 



Protection Period
 Severance Pay
   Severance Period
   Without Cause
 1.2 Interpretations .
 ARTICLE II
EMPLOYMENT AND DUTIES
 2.1 Term . Initial Term Renewal Term
 2.2 Position, Duties and Services .
 4




---



##### 



2.3 Compensation .
 Base Salary
 Bonuses and Perquisites
 Incentive, Savings, Profit Sharing, and Retirement Plans
 Welfare Benefit Plans
 2.4 Severance Benefit . ARTICLE III Section 2.1 ARTICLE III
 ARTICLE III
EARLY TERMINATION
 3.1 Death . Section 2.3
 3.2 Disability . Section 2.1 Section 2.3
 3.3 Termination for Cause or Voluntary Resignation by Key Employee .
 5




---



##### 



Section 2.3
 3.4 Termination Without Cause or for Good Reason Unrelated to a Change in Control . Section 2.1 Section 2.3
 3.5 Termination Without Cause or for Good Reason Related to a Change in Control . Section 2.3
 3.6 Termination of Companys Obligations . ARTICLE III Section
3.8
 3.7 Release . Section 3.7 Section 3.4 Section 3.5 i.e Section
2.3
 3.8 Non-Competition, Confidentiality .
 Agreement not to Compete Section 3.8(b) Section
3.8(b) Section
3.8
 6




---



##### 



Confidential Information
 Reasonableness of Restrictions Section 3.8 Section 3.8 Section 3.8 Section 3.8
 7




---



##### 



Enforcement Successor Employer Section 3.8 Section 3.8 Section 3.8
 3.9 Parachute Payments . ARTICLE III Section 3.9
 3.10 Payments Subject to Section 409A of the Code . ARTICLE III ARTICLE III
 8




---



##### 



ARTICLE IV
MISCELLANEOUS
 4.1 Governing Law .
 4.2 Amendment and Waiver .
 4.3 Severability .
 4.4 Entire Agreement . Section 2.3(c) Section 2.3(d)
 4.5 Withholding of Taxes and Other Employee Deductions .
 4.6 Headings .
 4.7 Actions by the Board .
 4.8 Construction .
  9




---



##### 



IN WITNESS WHEREOF,
 COMPANY:
ORION MARINE GROUP, INC.By:

/s/
Mark StaufferName:
    Mark StaufferTitle:
    Chief Financial OfficerKEY EMPLOYEE:/s/
J. Michael PearsonJ. Michael Pearson Signature Page to  Employment Agreement  (J. Michael Pearson)
[Federal Register Volume 89, Number 187 (Thursday, September 26, 2024)]
[Notices]
[Page 78902]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22090]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Senior Healthcare Innovation Consortium

    Notice is hereby given that, on July 10, 2024, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Senior Healthcare Innovation 
Consortium (``SHIC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Prudent Homecare, Bismarck, ND, and UnaliWear, Austin, 
TX, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and SHIC intends to file additional 
written notifications disclosing all changes in membership.
    On November 02, 2022, SHIC filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to section 6(b) of the Act on 
November 23, 2022 (87 FR 71677).
    The last notification was filed with the Department on April 4, 
2024. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on June 21, 2024 (89 FR 52094).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-22090 Filed 9-25-24; 8:45 am]
BILLING CODE P
Monica A. Duffy, Attorney Grievance Committee for the Third Judicial Department, Albany, for Attorney Grievance Committee for the Third Judicial Department.

Law Offices of Sarah Diane McShea, New York City (Sarah Diane McShea of counsel), for respondent.

Motion by respondent for an order reinstating her to the practice of law following her suspension by May 2019 order of this Court (Matter of Attorneys in Violation of Judiciary Law § 468-a, 172 AD3d 1706, 1732 [2019]; see Rules for Attorney Disciplinary Matters [22 NYCRR] § 1240.16; Rules of App Div, 3d Dept [22 NYCRR] § 806.16).

Upon reading respondent's notice of motion and affidavit with exhibits sworn to November 5, 2019, and upon reading the December 11, 2019 responsive correspondence from the Attorney Grievance Committee for the Third Judicial Department, and having determined, by clear and convincing evidence, that (1) respondent has complied with the order of suspension and the Rules of this Court, (2) respondent has the requisite character and fitness to practice law, and (3) it would be in the public interest to reinstate respondent to the practice of law (see Matter of Attorneys in Violation of Judiciary Law § 468-a [Serbinowski], 164 AD3d 1049, 1051 [2018]; Matter of Attorneys in Violation of Judiciary Law § 468-a [Ettelson], 161 AD3d 1478, 1479-1480 [2019]), it is

ORDERED that respondent's motion for reinstatement is granted; and it is further

ORDERED that respondent is reinstated as an attorney and counselor-at-law, effectively immediately.

Garry, P.J., Egan Jr., Lynch, Clark and Colangelo, JJ., concur.
<PAGE>

                                                                      Exhibit 23

                         INDEPENDENT AUDITORS' CONSENT
                         -----------------------------


The Board of Directors of
J.C. Penney Company, Inc.:


We consent to incorporation by reference in the Registration Statements on Form
S-8 (Nos. 33-28390, 33-59666, 33-66070, 33-66072, 333-13949, 333-22627, 333-
22607, 333-33343, 333-27329, 333-71237, 333-45536) and Form S-3 (No. 333-57019)
of J. C. Penney Company, Inc. of our reports dated February 22, 2001, relating
to the consolidated balance sheets of J. C. Penney Company, Inc. and
subsidiaries as of January 27, 2001 and January 29, 2000, and the related
consolidated statements of operations, stockholders' equity, and cash flows and
the financial statement schedule for each of the years in the three-year period
ended January 27, 2001, which reports are included or incorporated by reference
in the Annual Report on Form 10-K of J. C. Penney Company, Inc. for the year
ended January 27, 2001.


                                               /s/ KPMG LLP



Dallas, Texas
April 24, 2001
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM NATIONAL
PRESTO INDUSTRIES, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

                                                                       PAGE F-16
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               DEC-31-1995
<CASH>                                          91,448
<SECURITIES>                                   112,583
<RECEIVABLES>                                   38,566
<ALLOWANCES>                                     (450)
<INVENTORY>                                     25,605
<CURRENT-ASSETS>                               269,505
<PP&E>                                          16,646
<DEPRECIATION>                                 (9,337)
<TOTAL-ASSETS>                                 284,927
<CURRENT-LIABILITIES>                           38,186
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         7,441
<OTHER-SE>                                     239,300
<TOTAL-LIABILITY-AND-EQUITY>                   284,927
<SALES>                                        120,172
<TOTAL-REVENUES>                               120,172
<CGS>                                           77,376
<TOTAL-COSTS>                                   77,376
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   572
<INTEREST-EXPENSE>                                 687
<INCOME-PRETAX>                                 25,403
<INCOME-TAX>                                     6,434
<INCOME-CONTINUING>                             18,969
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    18,969
<EPS-PRIMARY>                                     2.61
<EPS-DILUTED>                                        0
        


</TABLE>
### F - 1 **Appendix F**  **:** Approve Parent/Guardian Information Letter and Opt
- out

### F - 2

Dear Parent or Guardian, Your school and district are taking part in a study conducted by the U.S. Department of Education. The study will be looking at a math training program for 4 th grade teachers called Developing Mathematical Ideas (DMI). Schools will either continue their regular program for training teachers to teach math or provide DMI to their 4 th grade teachers. Teachers will take p art in 24 hours of training in teaching 4 th grade math. They will also do homework and classroom exercises. We want to learn more about effective ways to help teachers teach math. Your child was chosen to be a part of this study because we are including all 4 th grade classrooms (where the teacher has decided to join the study). This study will not interrupt your child’s learning and there are no risks of any kind. As part of this study, your child will take a 30
-40 minute math test. The test will be given in their classroom during the last 4
- 6 weeks of school. Highly trained staff will give the test. We will also get your child’s state test scores from last year and information such as age and race. We will schedule testing so that your child does not miss class work. **You can take your child out of the study at any time. Also, your child does not have to answer any test questions he/she does not want to answer.**  Your district and school have decided to make this study a regular part of their program this year. This means that your child will take part in this study unless you sign the form below. If you **DO NOT** want your child to be a part of this study, please put your child’s name on the form and sign it. If you have any questions, please email me at ctran @inresg.org or call (714) 826
- 9600. Sincerely, Christopher Tran Study Manager

NOTE: Information collected for this study comes under the confidentiality and data protection requirements of the Institute of Education Sciences (The Education Sciences Reform Act of 2002, Title I, Part E, Section 183). Responses to this data collection will be used only for statistical purposes. The reports prepared for the st udy will summarize findings across the sample and will not associate responses with a specific district, school, or individual. We will not provide information that identifies you, your district or your school to anyone outside the study team, except as re quired by law.

### F - 3

To Whom It May Concern, I have read the letter. I have received a copy of the project description and hereby request that my child __________________________________ be excluded from the study.

(child’s name) My child attends __________ ____________________ Elementary School. I understand that my child will still attend their regular classroom as assigned by the school per their policies, in which the teacher has decided to participate in the study. **However ,**  **my child will not take the math test** **, nor will their school records be accessed for this study.** 

__________________________________ __________________________________ Parent/Guardian Signature Date
Exhibit 99


Written Statement of Chief Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002




The undersigned, the Chief Executive Officer of Colonial Properties Trust, the
general partner of Colonial Realty Limited Partnership (the "Partnership"),
hereby certifies that, to his knowledge on the date hereof:

(a)  the Form 10-Q of the  Partnership  for the period ended June 30, 2002 filed
     on the date  hereof  with  the  Securities  and  Exchange  Commission  (the
     "Report) fully complies with the  requirements of Section 13(a) or 15(d) of
     the Securities Exchange Act of 1934; and

(b)  information  contained  in the  Report  fairly  presents,  in all  material
     respects,  the  financial  condition  and  results  of  operations  of  the
     Partnership.



                                             /s/ Thomas H. Lowder
                                                 ----------------------
                                                 Thomas H. Lowder
                                                 Chief Executive Officer
                                                 August 14, 2002











<PAGE>



Written Statement of Chief Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002




The undersigned, the Chief Financial Officer of Colonial Properties Trust, the
general partner of Colonial Realty Limited Partnership (the "Partnership"),
hereby certifies that, to his knowledge on the date hereof:

(a)  the Form 10-Q of the  Partnership  for the period ended June 30, 2002 filed
     on the date  hereof  with  the  Securities  and  Exchange  Commission  (the
     "Report) fully complies with the  requirements of Section 13(a) or 15(d) of
     the Securities Exchange Act of 1934; and

(b)  information  contained  in the  Report  fairly  presents,  in all  material
     respects,  the  financial  condition  and  results  of  operations  of  the
     Partnership.






                                            /s/ Howard B. Nelson, Jr.
                                                ----------------------
                                                Howard B. Nelson, Jr.
                                                Chief Financial Officer
                                                August 14, 2002